HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action.

导出 OA

翻译打印收藏纠错

作者： Yoichi,Imai ^[1] ; Mitsuhito,Hirano ^[2] ; Masayuki,Kobayashi ^[3] ; Muneyoshi,Futami ^[4] ; Arinobu,Tojo ^[5]

作者单位： Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. imaiyo-tky@umin.ac.jp. ^[1] Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. m-hirano@ims.u-tokyo.ac.jp. ^[2] Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. masa-k@ims.u-tokyo.ac.jp. ^[3] Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. m-futami@umin.ac.jp. ^[4] Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. a-tojo@ims.u-tokyo.ac.jp. ^[5] Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. a-tojo@ims.u-tokyo.ac.jp. ^[6]

关键词 HDAC inhibitor HDAC6 HSP90 histone modification multiple myeloma panobinostat

DOI 10.3390/cancers11040475

PMID 30987296

发布时间 2020-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交